Medical guidelines meant to reduce risk for heart disease focus on levels of cholesterol in the blood, including low-density lipoproteins (LDL), labeled “bad cholesterol,” and high-density lipoproteins (HDL), labeled as “good.” Now, a new study suggests an important connection between good cholesterol particles in cerebrospinal fluid and brain health as well.
Researchers at the Keck School of Medicine of USC took samples of cerebrospinal fluid from people aged 60 and older and measured the amount of small HDL particles in each sample. The team found that a higher number of these particles in the fluid is associated with two key indicators that the particles might have a protective effect against Alzheimer’s disease.
One indicator is better performance on cognitive tests. The other indicator is higher circulating levels in the cerebrospinal fluid of a particular peptide — like a protein, but smaller — called amyloid beta 42. Although that peptide contributes to Alzheimer’s disease when it misfolds and clumps onto neurons, an increased concentration circulating around the brain and spine is actually linked to lower risk for the disease.
“This study represents the first time that small HDL particles in the brain have been counted,” said Hussein Yassine, M.D., an associate professor of medicine and neurology at the Keck School of Medicine of USC. “They may be involved with the clearance and excretion of the peptides that form the amyloid plaques we see in Alzheimer’s disease, so we speculate that there could be a role for these small HDL particles in prevention.”
Connections between HDL and brain health
The study has just been published in the journal Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association. The researchers recruited 180 healthy participants with an average age of nearly 77 and analyzed samples of their blood plasma and cerebrospinal fluid. Using a sensitive technique known as ion mobility, originally developed by study co-author Ronald Krauss, M.D., at the University of California, San Francisco, the investigators were able to identify, count and measure the size of individual HDL particles. A subset of 141 participants also completed a battery of cognitive tests.
Of the participants who took the cognitive tests, the ones with higher levels of small HDL particles in their cerebrospinal fluid performed better, independent of their age, sex, education or whether or not they carried the APOE4 gene, which puts them at higher risk for Alzheimer’s disease. The correlation was even stronger among those who had no cognitive impairment. The evidence suggests that these HDL particles may be key to finding treatments that would work early in the disease process, long before cognitive decline occurs.
“What we’re finding here is that before the onset of cognitive impairment, these oils — these small HDL particles — are lubricating the system and keeping it healthy,” he said. “You’ve got a time to intervene with exercise, drugs or whatever else to keep brain cells healthy. We still need to understand the mechanisms that promote the production of these particles, in order to make drugs that increase small HDL in the brain.”
A fresh Alzheimer’s research direction and the potential for prevention
Yassine and his team were led to study HDL particles in the brain because of the many ways they keep the brain healthy. They help form the sheathes that insulate the brain and nerve cells so they can quickly communicate amongst themselves, and they play a role in the growth and repair of neurons. They also appear to help prevent inflammation to the barrier between the brain and blood system, which can result in cognitive decline.
But unlike most HDL in the blood, HDL particles in the brain are smaller and need a protein called apolipoprotein E, or ApoE, to do all that work. The strongest risk factor for Alzheimer’s disease, the APOE4 gene, is a mutation or variant of the APOE gene that encodes that very same protein.
Yassine and his colleagues already have studies underway using electron microscopy — which can capture images down to the molecular level — in order to better understand the structure and function of ApoE HDL. They also hope to study ApoE HDL and Alzheimer’s risk over time in larger groups of participants, with an eye toward elucidating factors such as the effects of medications and of diseases including diabetes.
“People are realizing that there is more to late-onset Alzheimer’s disease,” Yassine said. “Perhaps it’s equally interesting to see how lipids are interacting with amyloid or how newer treatments can be focused not just on amyloid or tau, but also on fats and ApoE.”
About this study
Co-first authors of the study are Ashley Martinez of the Keck School of Medicine of USC, Gali Weissberger of Bar Ilan University and Zsuzsanna Kuklenyik of the Centers for Disease Control and Prevention. Other authors are Xulei He, Cristiana Meuret, Trusha Parekh, Jon Rees, Bryan Parks, Michael Gardner, Melanie Sweeney, Michael Harrington, Xinhui Wang, Berislav Zlokovic, Elizabeth Joe, Lon Schneider, Helena Chui, John Barr and Duke Han, all of USC; Sarah King of UCSF; Timothy Collier of Quest Diagnostics in Cleveland; and Daniel Nation of the University of California, Irvine.
The study was supported by the National Institute on Aging (R21AG056518, R01AG055770, R01AG054434, R01AG067063, R01AG055430, RF1AG068166, R01AG033078, RF1AG054068, P50AG005142, P30AG066530. P01AG052350, T32AG000037, P01AG052350, R01AG039452, R01AG023084, P30AG066530, AG058162, R56AG069130, R01AG072490); the National Institutes of Health (P50GM115318, P01G052350); the National Institute of Environmental Health Science (R01ES025888, ES025888); the Centers for Disease Control and Prevention; the L.K. Whittier Foundation; the Huntington Medical Research Institutes; the Dairy Research Institute; the Alzheimer’s Association (strategic 509279 grant); the Cure Alzheimer’s Fund; the Foundation Leducq Transatlantic Network of Excellence for the Study of Perivascular Spaces in Small Vessel Disease; the Della Martin Foundation; Quest Diagnostics; and Saliogen. The Batey Foundation funded instrumentation used for ion mobility analysis.
About Keck School of Medicine of USC
Founded in 1885, the Keck School of Medicine of USC is one of the nation’s leading medical institutions, known for innovative patient care, scientific discovery, education and community service. Medical and graduate students work closely with world-renowned faculty and receive hands-on training in one of the nation’s most diverse communities. They participate in cutting-edge research as they develop into tomorrow’s health leaders. The Keck School faculty are key participants in training of 1200 resident physicians across 70 specialty and subspecialty programs, thus playing a major role in the education of physicians practicing in Southern California.
Alzheimers Disease & Dementia
Method of Research
Subject of Research
The small HDL particle hypothesis of Alzheimer’s disease
Article Publication Date
Hussein N. Yassine is the 2019-2021 co-chair of the NMD PIA of the Alzheimer’s Association (non-paid). Michael G. Harrington received honorarium as guest speaker at annual Headache Cooperative of the Pacific and NIH ZRG1 BDCN-W Study Section Meetings. Lon S. Schneider receives consulting fees from Abbott, AC Immune, Avraham, Ltd, Boehringer Ingelheim, Cognition Therapeutics, Cortexyme, Eisai, FujiFilm, Immunobrain Checkpoint Ltd, Neurally Inc, Neurim Ltd, Neuronix Ltd, Novo-Nordisk, Samus, Takeda, and vTv. Helena C. Chui is on the external advisory board to Oregon Health Science University Alzheimer’s Disease Research Center, and on the Alzheimer Los Angeles Board member and Chair of Medical Scientific Advisory Council (both non-paid). Timothy S. Collier is an employee of Quest Diagnostics and has stocks in Quest Diagnostics. S. Duke Han receives consulting fees from Rush University Medical Center and participates in the AARP Global Council on Brain Health. Ronald M. Krauss reports receiving a grant from Quest Diagnostics, royalties from Lawrence Berkeley National Laboratory for patents for ion mobility methodology, and consulting fees from Saliogen Therapeutics and Merck. All the other authors declare that they have no